Nurix therapeutics to participate in the 2023 rbc capital markets global healthcare conference

San francisco, may 09, 2023 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that arthur t. sands, m.d., ph.d., nurix's president and chief executive officer, will participate in a fireside chat at the 2023 rbc capital markets global healthcare conference on wednesday, may 17th at 4:35 p.m. et.
NRIX Ratings Summary
NRIX Quant Ranking